Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | F13A1 | P00488 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | TGM1 | P22735 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607607 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3F13A1 | |
| SCHEMBL10145613 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3F13A1 | |
| SCHEMBL30700601 | 0.86 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3PREP | |
| SCHEMBL609610 | 0.86 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3PREP | |
| SCHEMBL609346 | 0.86 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3PREP | |
| SCHEMBL24909283 | 0.86 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3PREP | |
| SCHEMBL16584672 | 0.86 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3PREP | |
| SCHEMBL20713877 | 0.83 | CHRM2 (0.47) | NR1H2CHRM2CHRM1CHRM3F13A1 | |
| SCHEMBL19865492 | 0.83 | CHRM2 (0.47) | NR1H2CHRM2CHRM1CHRM3F13A1 | |
| SCHEMBL21154007 | 0.82 | CHRM2 (0.40) | NR1H2CHRM2CHRM1CHRM3F13A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | NR1H2 66/4885CHRM2 396/4885CHRM1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.